Baxter International Inc. BAX
23.37
(0.11)
(0.47%)
as of 25 Sep
- Market cap
- $12.2B
- P/E
- 0.0×
Follow BAX
Indexes
indicate stock being part of an index,
Growth Flags
show if company had growth for consecutive years
Baxter International Inc. (BAX) P/E ratio
Baxter International Inc. has no meaningful P/E ratio: its trailing twelve-month earnings is negative. Over the past ten years it has ranged from 0.0× (September 2026) to 190× (September 2024) — the current reading is the lowest in ten years.
P/E ratio, daily
Annual
| Period | P/E ratio | Change |
|---|---|---|
| FY2025 | 0.0× | — |
| FY2024 | 0.0× | — |
| FY2023 | 7.4× | — |
| FY2022 | 0.0× | — |
| FY2021 | 33.5× | (9.74%) |
| FY2020 | 37.1× | (10.26%) |
| FY2019 | 41.4× | 91.19% |
| FY2018 | 21.7× | (57.45%) |
| FY2017 | 50.9× | 937.42% |
| FY2016 | 4.9× | (77.22%) |
Quarterly
| Period | P/E ratio | Change |
|---|---|---|
| Jun 2026 | 0.0× | — |
| Mar 2026 | 0.0× | — |
| Dec 2025 | 0.0× | — |
| Sep 2025 | 0.0× | — |
| 42 more quarters | Free account |
Against its own ten years
Low 0.0×
High 190×
Ten-year median
16.9×
Current reading's percentile
23
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| AVTR Avantor, Inc. compare | n/m |
| BAX Baxter International Inc. | n/m |
| BLCO Bausch + Lomb Corporation compare | n/m |
| SOLV Solventum Corporation compare | 10.9× |
| COO The Cooper Companies, Inc. compare | 18.9× |
| ATR AptarGroup, Inc. compare | 22.1× |
| ALGN Align Technology, Inc. compare | 25.5× |
| STVN Stevanato Group S.p.A. compare | 37.7× |
| RGEN Repligen Corporation compare | 253× |
| Medical Instruments & Supplies industry median | 34.2× |
| Healthcare sector median | 22.7× |
| Market median | 17.9× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)
More on BAX
- Revenue
- Net income
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- The full statement